{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Stage+Stage+IIIB&page=3", "query": { "condition": "Melanoma Stage Stage IIIB", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 147, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Stage+Stage+IIIB&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Stage+Stage+IIIB&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T07:21:37.861Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01258855", "title": "Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Recurrent Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Ziv-Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 84, "start_date": "2011-01-18", "completion_date": "2018-03-29", "has_results": true, "last_update_posted_date": "2019-05-10", "last_synced_at": "2026-10-06T07:21:37.861Z", "location_count": 21, "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01258855" }, { "nct_id": "NCT03767348", "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)", "Microsatellite Instability-High (MSI-H)", "Non-melanoma Skin Cancer (NMSC)", "Cutaneous Melanoma" ], "interventions": [ { "name": "RP1", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2017-09-20", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-06T07:21:37.861Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03767348" }, { "nct_id": "NCT02519322", "title": "Neoadjuvant and Adjuvant Checkpoint Blockade", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Mucosal Melanoma", "Ocular Melanoma", "Stage III Acral Lentiginous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Uveal Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IIIC Uveal Melanoma AJCC v7", "Stage IV Acral Lentiginous Melanoma AJCC v6 and v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2016-02-02", "completion_date": "2023-01-26", "has_results": true, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-10-06T07:21:37.861Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02519322" }, { "nct_id": "NCT02910700", "title": "Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2016-12-09", "completion_date": "2027-12-08", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-06T07:21:37.861Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02910700" }, { "nct_id": "NCT01274338", "title": "Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma of Unknown Primary", "Recurrent Melanoma", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1673, "start_date": "2011-06-17", "completion_date": "2027-02-02", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-06T07:21:37.861Z", "location_count": 928, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 580 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01274338" }, { "nct_id": "NCT03769155", "title": "VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "VX15/2503", "type": "BIOLOGICAL" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-12-13", "completion_date": "2032-12-15", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-06T07:21:37.861Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03769155" }, { "nct_id": "NCT04990726", "title": "Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Melanoma, Stage II", "Melanoma Stage IV" ], "interventions": [ { "name": "Assessment", "type": "BEHAVIORAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2019-12-05", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-06T07:21:37.861Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990726" }, { "nct_id": "NCT00715793", "title": "Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hussein Tawbi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2008-06", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-10-03", "last_synced_at": "2026-10-06T07:21:37.861Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00715793" }, { "nct_id": "NCT01638533", "title": "Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Hematopoietic and Lymphoid Cell Neoplasm", "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Neuroendocrine Neoplasm", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Colorectal Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Melanoma", "Recurrent Pancreatic Carcinoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage III Breast Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Cutaneous Melanoma AJCC v7", "Stage III Lung Cancer AJCC v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage III Prostate Cancer AJCC v7", "Stage III Renal Cell Cancer AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Lung Cancer AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2012-08-03", "completion_date": "2020-09-01", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-10-06T07:21:37.861Z", "location_count": 11, "location_summary": "Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01638533" }, { "nct_id": "NCT00390338", "title": "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "polarized dendritic cells", "type": "BIOLOGICAL" }, { "name": "non-polarized dendritic cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pawel Kalinski", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2006-10", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2017-09-26", "last_synced_at": "2026-10-06T07:21:37.861Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00390338" } ] }